Enhanced Alpha-Emitter Radiation Therapy with Controlled Radon Release and Real-Time Beta Radiation Supplement

A novel radiation therapy system that combines alpha-emitter radiation with controlled radon release and real-time beta radiation supplement, providing a more efficient and personalized treatment for cancer patients.

The original patent disclosed an interstitial source with combined alpha and non-alpha radiation for cancer treatment. However, it had limitations in controlling radon release and optimizing beta radiation. The new inventive concept addresses these limitations by introducing a controlled desorption probability of radon release and a real-time beta radiation supplement module, ensuring a more efficient and safe treatment.

The system comprises a radiation source with a controlled desorption probability of radon release, which is achieved through a specialized coating. The radiation source is paired with a beta radiation supplement module that can be adjusted in real-time to optimize the treatment. The system also includes a real-time radiation monitoring module to ensure safe and effective treatment. The radiation source can be personalized for individual patients based on their tumor characteristics, providing a more targeted treatment.

The new inventive concept introduces the controlled desorption probability of radon release, which is a significant improvement over the original patent. The real-time beta radiation supplement module and the personalization feature based on tumor characteristics are also novel and non-obvious aspects of the invention.

Alternative embodiments of the inventive concept could include different types of radiation sources, such as seeds or wires, and various methods for controlling radon release. The system could also be adapted for use in different types of cancer treatment, such as external beam radiation therapy.

The enhanced alpha-emitter radiation therapy system has significant commercial potential in the cancer treatment market, particularly in the area of personalized medicine. The system's ability to provide real-time monitoring and adjustment of beta radiation could lead to improved treatment outcomes and increased patient safety, making it an attractive option for hospitals and cancer treatment centers.